CML on tyrosine kinase inhibitors: response milestones and resistance
- Treatment and support
A daily pill turned chronic myeloid leukaemia into a long-term condition, but only if it is taken every day and its effect is measured on schedule.
What it is
Chronic myeloid leukaemia (CML) is driven by the BCR::ABL1 fusion, a tyrosine kinase that is always on. Tyrosine kinase inhibitors (TKIs) block it: imatinib (first generation), dasatinib, nilotinib and bosutinib (second generation), ponatinib (third generation) and asciminib (which binds a different pocket of the kinase). Response is followed by quantitative PCR for BCR::ABL1 transcripts reported on the International Scale (IS), which lets results from different laboratories be compared.
What to know
- Milestones by principle: BCR::ABL1 at or below 10% IS at 3 months, below 1% by 6 months, at or below 0.1% (major molecular response, MMR) by 12 months; deeper responses are MR4 (0.01%) and MR4.5.
- A result above 10% at 6 months, above 1% at 12 months or later, or a new resistance mutation is treatment failure and needs action.
- The commonest cause of failure is not taking the drug every day; next come drug interactions, poor absorption and kinase domain mutations.
- The T315I mutation resists imatinib, dasatinib, nilotinib and bosutinib; ponatinib and asciminib remain active.
- Side effects differ by drug: imatinib, swelling and muscle cramps; dasatinib, pleural effusions and pulmonary hypertension; nilotinib, QT prolongation, high glucose and arterial narrowing; bosutinib, diarrhoea and liver enzymes; ponatinib, arterial clots and high blood pressure.
- With a sustained deep response for several years, some patients can stop the TKI under close PCR monitoring (treatment-free remission); about half stay in remission, and most who relapse respond again when the drug is restarted.
How it is done (and why)
- Confirm the diagnosis and phase: count, smear, marrow with cytogenetics, and baseline quantitative BCR::ABL1 PCR.
- Choose the TKI by the patient: other illnesses (heart, lungs, pancreas, diabetes), drug interactions, risk score and goals such as stopping later.
- Check the full count often in the first weeks: TKIs can lower counts while normal blood cells recover.
- Measure BCR::ABL1 by PCR (IS) every 3 months until MMR is reached, then every 3 to 6 months.
- Milestone missed: check adherence, interacting drugs and how the pill is taken, then test for kinase domain mutations.
- Change TKI according to the mutation and side effects; progression or multiple failures: consider allogeneic stem cell transplantation.
- Sustained deep response for years: discuss a supervised attempt to stop, with monthly PCR at first.
The TKIs side by side (generic names, no doses)
| Drug | Generation and binding | Classic side effects to watch | Note |
|---|---|---|---|
| Imatinib | First; ATP pocket | Swelling around the eyes, fluid retention, muscle cramps, nausea | Longest experience; slower deep responses |
| Dasatinib | Second; ATP pocket | Pleural effusion, pulmonary hypertension, low platelets | Absorption falls with acid-suppressing drugs |
| Nilotinib | Second; ATP pocket | QT prolongation, high glucose and lipids, pancreatitis, arterial narrowing | Taken on an empty stomach; ECG before and during |
| Bosutinib | Second; ATP pocket | Diarrhoea, raised liver enzymes | An option first line or when other TKIs are not tolerated |
| Ponatinib | Third; ATP pocket | Arterial occlusion, high blood pressure, liver toxicity | Active against T315I |
| Asciminib | Binds the myristoyl pocket (allosteric) | Low counts, raised pancreatic enzymes | Active against T315I |
Risks and precautions
- TKIs are metabolised largely by CYP3A4: strong inhibitors (some azole antifungals, macrolides, grapefruit) raise levels and inducers (rifampicin, some antiepileptics, St John's wort) lower them.
- TKIs can harm a fetus: pregnancy is planned with the haematologist, usually during a deep, stable response.
- Before nilotinib or dasatinib, assess the heart and lungs; in patients with vascular disease, the arterial risk of nilotinib and ponatinib weighs heavily.
- Taking a pill every day for years is hard: ask about missed doses kindly and often, and look for cost, side effects or depression as the reason.
- Accelerated or blast phase behaves like acute leukaemia and needs urgent specialist care, TKI plus chemotherapy and often transplantation.
Monitoring and next step
- Quantitative BCR::ABL1 PCR on the International Scale every 3 months until MMR, then every 3 to 6 months; monthly in the first months after stopping a TKI.
- Full count every one to two weeks at the start, then less often once stable.
- Kinase domain mutation testing when a milestone is missed, a response is lost or the disease progresses.
- Drug-specific checks: ECG for QT with nilotinib, glucose and lipids with nilotinib, chest imaging if breathless on dasatinib, liver tests and blood pressure for all.
- A rising PCR in a patient who has been well: first ask about adherence and new medicines, then repeat the PCR.
Common traps
- Testing for mutations before asking about adherence: missed pills are the commonest reason a milestone is missed.
- Comparing PCR results off the International Scale, or across laboratories without standardisation: such results are not comparable.
- Switching from one ATP-pocket TKI to another in a T315I mutation: only ponatinib or asciminib work.
- Starting a strong CYP3A4 inhibitor or an acid suppressant on a TKI: check the interaction first.
- Stopping a TKI outside a monitored programme: relapse may be missed until it is no longer a quiet molecular one.
Test yourself
Think of the answer, then tap the question to see it.
At 12 months on imatinib, BCR::ABL1 is 2% IS. What should be checked first, before changing the drug?
Whether the patient takes the pill every day and any interacting drugs; then kinase domain mutation testing, and switching to another TKI.
Why does a patient with the T315I mutation not respond to switching from imatinib to dasatinib?
T315I blocks binding of all first- and second-generation ATP-pocket TKIs; ponatinib or asciminib (binding another pocket) are needed.
Which TKI would you avoid in a patient with recurrent pleural effusions, and why?
Dasatinib, because fluid around the lungs (pleural effusion) is its typical side effect.
Why must PCR results be reported on the International Scale?
It standardises results between laboratories against a common baseline, so milestones such as 10%, 1% and 0.1% mean the same everywhere.
Elsewhere in DurgiPedia
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); Chronic myelogenous leukemia (CML) (MedlinePlus, US National Library of Medicine, 2024); Imatinib: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025); Chronic myeloid leukemia: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
